Search results for 'Placebo'
Phase III trial demonstrates rapid efficacy of Zelrix in treating acute migraine
NuPathe Inc., a specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, today announced data from the pivotal Phase III trial of Zelrix™, a novel transdermal patch in clinical development for the treatment of acute migraine. Zelrix combines NuPathe’s proprietary SmartRelief™ iontophoretic transdermal technology with sumatriptan, the most prescribed treatment for acute migraine in the United States.
http://www.news-medical.net/news/20090910/Phase-III-trial-demonstrates-rapid-efficacy-of-Zelrix-in-treating-acute-migraine.aspx
PROTECT clinical study aimed at the assessment of rolofylline effects
Despite the promising findings of the PROTECT Pilot study, the larger PROTECT trial found no difference with rolofylline versus placebo with respect of the primary and main secondary end-points of the study. Although more rolofylline patients than placebo patients experienced moderate or marked dyspnea improvement at 24 and 48 hours from randomization, this was counterbalanced by a lack of effect on persistent renal impairment. Lastly, the risk of important neurological events was increased in patients on rolofylline.
http://www.news-medical.net/news/20090902/PROTECT-clinical-study-aimed-at-the-assessment-of-rolofylline-effects.aspx
Positive results obtained from phase 3 clinical trial of lurasidone for treating schizophrenia
Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today positive results from PEARL 2 - a phase 3 clinical trial of lurasidone for the treatment of patients with schizophrenia. In this trial, both lurasidone 40 and 120 mg/day were significantly more effective than placebo for the treatment of schizophrenia. Lurasidone was well-tolerated with an overall discontinuation rate that was similar to placebo.
http://www.news-medical.net/news/20090826/Positive-results-obtained-from-phase-3-clinical-trial-of-lurasidone-for-treating-schizophrenia.aspx
Cimzia approved in U.S. for rheumatoid arthritis
UCB announced today that the U.S. Food and Drug Administration (FDA) approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).
http://www.news-medical.net/news/2009/05/13/Cimzia-approved-in-US-for-rheumatoid-arthritis.aspx
Abilify (aripiprazole) approved for acute treatment of bipolar I disorder in adolescents
Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for ABILIFY (aripiprazole) for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder, with or without psychotic features in pediatric patients (10 to 17 years old).
http://www.news-medical.net/news/2008/03/01/35776.aspx
Positive results from trial of investigational anti-epilepsy drug Brivaracetam
UCB has announced data demonstrating that anti-epileptic drug (AED) brivaracetam, with the proposed trade name Rikelta, administered as an adjunctive treatment in adults with refractory epilepsy with partial onset seizures, significantly reduced seizure frequency and had a side-effect profile comparable to placebo.
http://www.news-medical.net/news/2007/12/04/33188.aspx
Promising trial results show biologic therapy ustekinumab significantly improved psoriasis
The first reported findings from an international, Phase 3 study showed that more than two-thirds of patients with moderate to severe plaque psoriasis receiving two doses of ustekinumab (CNTO 1275) achieved at least a 75 percent reduction in psoriasis at week 12, the primary endpoint of the study, as measured by the Psoriasis Area and Severity Index (PASI 75).
http://www.news-medical.net/news/2007/10/04/30792.aspx
New study explains placebo effect
Why do some people experience a “placebo effect” that makes them feel better when they receive a sham treatment they believe to be real — while other people don't respond at all to the same thing, or even feel worse?
http://www.news-medical.net/news/2007/07/19/27805.aspx
Researchers pinpoint brain region linked to placebo effect
Researchers have pinpointed a brain region central to the machinery of the placebo effect, the often controversial phenomenon in which a person's belief in the efficacy of a treatment such as a painkilling drug influences its effect.
http://www.news-medical.net/news/2007/07/19/27793.aspx
Study of Aripiprazole in adolescents with schizophrenia
In a six-week study in adolescents (13-17 years old) with schizophrenia, the Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company atypical antipsychotic aripiprazole demonstrated significant improvement compared to placebo on the primary efficacy endpoint, Positive and Negative Syndrome Scale (PANSS) Total Score.
http://www.news-medical.net/news/2007/05/24/25587.aspx
Study looks at placebo effect
The debate about the existence of a placebo effect has heated up over the past year as more and more lab experiments are detecting immediate physiological responses to placebos.
http://www.news-medical.net/news/2006/02/02/15720.aspx
Placebos can affect emotion as well relieving pain
Just as placebos have been shown to bring relief from pain, researchers have now found that they can affect emotion, alleviating the impact of unpleasant experiences.
http://www.news-medical.net/news/2005/06/15/11053.aspx
Rimonabant study shows significant improvements in HbA1c and cardiometabolic risk factors in people with type 2 diabetes
The reported results of a one-year phase III study in 1045 people with type 2 diabetes treated with rimonabant, the first in a new class of therapeutic agents called selective CB1 Blockers, were that rimonabant 20 mg significantly improved HbA1c (a measure of blood sugar control), dyslipidemia (abnormal levels of fat in the blood), and systolic blood pressure with a concomitant substantial reduction in abdominal obesity in people with type 2 diabetes treated with oral anti-diabetic medications and requiring further control.
http://www.news-medical.net/news/2005/06/12/10936.aspx
New study confirms benefits of rimonabant in weight loss
Phase III clinical study comparing placebo to rimonabant, the first agent in a new therapeutic class known as selective cannabinoid type 1 (CB1) blockers, showed that overweight or obese people taking rimonabant 20mg once daily benefited from a significant reduction in their body weight
http://www.news-medical.net/news/2004/08/29/4383.aspx
News-Medical.Net provides this medical information service in accordance
with these
terms and conditions.
Please note that medical information found
on this website is designed to support, not to replace the relationship
between patient and physician/doctor and the medical advice they may provide.
Subscribe